TNTyler B. Nofzinger

Tyler B. Nofzinger

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Tyler B. Nofzinger has a total of 23 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Management Patterns, Outcomes, and Timing Differences in Carpal Tunnel Syndrome Treatment: A Retrospective Review at a Single Institution from 2019-2024

    by Christopher Eduard Lingat, Usama N. Ismail, Gaurang M. Amonkar, Derek S. Anderson, Alexander Chueh, Sajan Goyal, Timothy T. Huang, Justin Kim, Laya P. Krishnan, Tyler B. Nofzinger, et al.

    Background: Carpal tunnel syndrome (CTS) is the most common peripheral entrapment neuropathy that may be managed with conservative therapies and/or surgical decompression. Although both strategies are routinely used, limited data exists on how management patterns evolve within individual healthcare systems over time. This study examined trends in CTS treatment utilization, timing to surgery, and patient outcomes over a five-year period. Methods: A retrospective cohort study of adult patients diagnosed with CTS at the Carle Health System between September 1st, 2019 and September 1st, 2024 was conducted. Eligible records were identified through the electronic medical record and manually reviewed. Data collected included non-surgical and surgical treatments used, symptom improvement, follow-up completion, and timing intervals for injections and carpal tunnel release (CTR). Descriptive statistics were generated, and Fisher’s exact and Kruskal-Wallis tests were used to explore annual differences. All inferential analysis were considered exploratory due to small sample size. Results: Of 516 identified patients, 62 met inclusion criteria. Across the study period, the proportion of patients receiving wrist splinting (43-73%) and CTR (43-73%) remained relatively stable, with CTR performed in 60% of patients overall. Management pathway distributions, non-surgical only (27%), surgical only (13%), both (47%), or no treatment (13%), did not differ significantly across years (p >0.05). Among patients receiving injections, 70% reported symptom improvement, while postoperative CTR cure rate was found to be 95%. CTR follow-up was completed in 73% of surgical patients. Median time from diagnosis to injection was 289 days, from diagnosis to CTR was 143 days, and from surgery to follow-up was 13 days, with no significant temporal differences (p>0.05). Conclusions: CTS management patterns at the Carle Health System have remained consistent from 2019-2024, with high rates of surgical success and variable time to intervention. Although sample size and documentation variability were limiting factors, these finding provide a baseline characterization of local practice and highlight opportunities to improve referral efficiency and postoperative follow-up. Larger studies are needed to better define the progression of CTS care trends.

  • Open Access

    Incidence of meningioma in women with a history of combined oral contraceptive pill use and polycystic ovary syndrome

    by Emily Edwards, Kathryn Tsai, Suguna Pappu, Heidi Gaddey, Tyler B. Nofzinger, Emily Vachon, Bryan McConomy

    Background: Meningiomas, benign central nervous system tumors, express progesterone and estrogen receptors. Their proliferation has been associated with hormonal and demographic factors, including female sex, obesity, and race. Prior studies on oral contraceptive pill (OCP) use and meningioma risk have been limited in their analysis of the modifying effects of race, obesity, and polycystic ovary syndrome (PCOS). Objectives: To assess the association between combined OCP use and meningioma development, and to assess how race, obesity, and PCOS influence this relationship. Design: Retrospective cohort study using aggregated electronic health record data in Epic Cosmos. Methods: Women aged 13–50 from 2005 to 2023 with and without combined OCP use were identified. Patients with history of radiation, neurofibromatosis 2, progestin-only contraceptive use, and hormone replacement therapy were excluded. The cohort was then stratified by PCOS status, obesity, and race. Results: Combined OCP users saw a 40% lower risk of meningioma compared to non-users. PCOS was associated with a bidirectional effect on meningioma risk, modified by obesity. Among patients with obesity, those with PCOS had a 30% lower risk of developing meningioma compared to those without PCOS. Among non-obese patients, those with PCOS had a 108% greater risk of developing meningioma compared to those without PCOS. After adjusting for both PCOS and obesity, women with a history of combined OCP usage had 42% reduced odds of developing meningioma. When stratified by race, combined OCP use was associated with 47% decreased risk in White patients, 34% lower risk in Black patients, and 28% lower risk in Asian patients. Controlling for race overall, combined OCP use remained significantly protective, with 43% reduced odds of meningioma development. Conclusion: Findings suggest a potential protective association between combined OCP use and meningioma that remained significant after controlling for obesity, PCOS status, and race. Additionally, this study found that meningioma risk in patients with PCOS differed based on obesity status.


  • Open Access

    Vaccine fatigue and influenza vaccination trends across Pre-, Peri-, and Post-COVID-19 periods in the United States using epic’s cosmos database

    by Tyler B. Nofzinger, Timothy T. Huang, Christopher Eduard R. Lingat, Gaurang M. Amonkar, Emily E. Edwards, Albert Yu, Alexander D. Smith, Nasser Gayed, Heidi L. Gaddey

    Introduction: Influenza vaccination is a critical public health measure, especially amidst the challenges of the COVID-19 pandemic. This study uses Epic’s Cosmos database to analyze influenza vaccination trends across demographic groups in the United States, examining the effects of the COVID-19 pandemic and “vaccine fatigue” on influenza vaccination rates. Methods: This retrospective cross-sectional study analyzes influenza vaccination rates pre- (1 May 2018–31 May 2019), peri- (1 May 2020–31 May 2021), and post-COVID-19 (1 May 2023–31 May 2024). A two-proportion z-test and Cohen’s h test were calculated to assess statistical significance. Results: Influenza vaccination rates increased peri-COVID (+1.99% point change, h = 0.04, p < 0.001) and decreased post-COVID (−6.41% point change, h = 0.14, p < 0.001) relative to pre-COVID. The largest changes were observed in the following groups: 5−18 year olds (−13.92% point change, h = 0.31, p < 0.001), 19−26 year olds (−9.91% point change, h = 0.25, p < 0.001), American Indian or Alaska Native (−8.11% point change, h = 0.18, p < 0.001), Other Races (−7.36% point change, h = 0.17, p < 0.001), White (−6.89% point change, h = 0.15, p < 0.001), and the South U.S. census region (−7.21% point change, h = 0.17, p < 0.001). Conclusion: Post-pandemic influenza vaccination compliance decreased relative to pre-pandemic, especially among younger age groups, certain racial groups, and in the southern U.S. These findings suggest that the COVID-19 pandemic negatively impacted influenza vaccination compliance. While overall trends aligned with publicly available data, absolute counts may be under-reported within Epic due to incomplete documentation of vaccine administrations outside of Epic-affiliated systems.